Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG1662 granules · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Granules Fasted | EXPERIMENTAL | - |
| Granules Fed | EXPERIMENTAL | - |
| Tablet Fasted | ACTIVE_COMPARATOR | - |
| Tablet Fed | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RG1662 granules | DRUG | Single dose, oral administration of RG1662 immediate release granules |
| RG1662 tablet | DRUG | Single dose, oral administration of film-coated RG1662 immediate release tablet |
Inclusion Criteria: * Male or female volunteers, 18 to 60 years of age, inclusive Exclusion Criteria: * A history of epilepsy, convulsions or significant head injury * Any other clinically relevant abnormalities, concomitant diseases or ongoing medical conditions
RG1662 granules is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its bioavailability compared to a film-coated tablet formulation. The drug is being developed by Roche Holding AG.
RG1662 granules is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company conducted a Phase 1 clinical trial to compare the bioavailability of the granule formulation with a film-coated tablet version of RG1662.
RG1662 granules is in Phase 1 clinical development. A single Phase 1 trial has been completed, involving 18 healthy volunteers in the United Kingdom. The drug is investigational and has not been approved by regulatory authorities.
RG1662 granules has one completed clinical trial, NCT02194244, titled 'Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662'. This Phase 1 study enrolled 18 healthy volunteers in the United Kingdom and was active-controlled, though not double-blinded.
RG1662 granules is a formulation of the investigational drug RG1662. The granule form was studied in a Phase 1 trial to compare its bioavailability with the film-coated tablet formulation of RG1662. Both are being developed by Roche Holding AG.